Filter posts

The Arrival of Actionable Personalized Medicine

The pace of implementation of next-generation sequencing (NGS) in a clinical context, which almost rivals …

A Manhattan Project for Alzheimer's Disease

Earlier this month, at the Alzheimer’s Disease Summit in New York City, BIO‘s President & …

Bridging Research to Cures: Summit for R&D Companies

As human and animal health companies struggle to advance medical innovation while managing costs, the …

BIO Patient and Health Advocacy Summit: Patient-Focused Drug Development

Panelists in this morning’s opening session outlined strategies for the FDA to better engage the …

Uniting To Accelerate Pediatric Medicine

Drug companies inherently absorb significant risk when developing compounds and biologics for clinical use. A …

New CDC Report on Alarming Rates of Antibiotic-Resistant Infections

Every year in the United States, 2 million people acquire an antibiotic-resistant infection. Of those, at …

FDA Consumer Update: Advances in Saving Lives with Blood

Every two seconds in the U.S., someone needs a blood transfusion or blood product—people of …

CTTI: Use of Central IRBs in Multi-Center Trials to Streamline Clinical Research

Multi-center clinical trials can provide high-quality, statistically-sound evidence to answer medical questions. Earlier this year, …

New PhRMA Report: Nearly 300 Vaccines Currently in Development

Today, the Pharmaceutical Research and Manufacturers of America released a report, Medicines in Development: Vaccines …

NCATS R&D Day Aimed At Linking Investors to Preclinical Drug Development Projects

On behalf of the National Center for Advancing Translational Sciences (NCATS), I invite BIO stakeholders …